MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find tha...
Main Authors: | Kerry, J, Godfrey, L, Repapi, E, Tapia, M, Blackledge, N, Ma, H, Ballabio, E, O'Byrne, S, Ponthan, F, Heidenreich, O, Roy, A, Roberts, I, Konopleva, M, Klose, R, Geng, H, Milne, T |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
Cell Press
2017
|
Títulos similares
-
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia
por: Jon Kerry, et al.
Publicado: (2017-01-01) -
MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.
por: Godfrey, L, et al.
Publicado: (2016) -
The role of DOT1L in MLL-AF4 leukaemia
por: Godfrey, L
Publicado: (2018) -
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.
por: Ballabio, E, et al.
Publicado: (2012) -
P314: THERAPEUTICALLY TARGETING THE UNIQUE BARCODE OF MLL/AF4
por: R. Cameron, et al.
Publicado: (2022-06-01)